CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02680665
NCT02680665N/ACompleted

AMEPAROMO CAPSULES 250 MG DRUG USE INVESTIGATION

Pfizer·observational·Posted Feb 11, 2016·Updated Dec 9, 2020

In Brief

An observational study for Intestinal Amebiasis. Completed, enrolled 120 participants.

Detailed Summary

This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 11, 2016
Enrollment StartOct 19, 2015
Primary CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.4 years ago